Skip to main content
Top
Published in: Current Infectious Disease Reports 4/2016

01-04-2016 | Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis

Authors: Kimberly J. Alvarez, Arlene Smaldone, Elaine L. Larson

Published in: Current Infectious Disease Reports | Issue 4/2016

Login to get access

Abstract

Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality worldwide. The magnitude of the HCV burden has previously been the subject of debate, as representative data tend to exclude high-risk populations, including institutionalized persons. The purpose of this systematic review and meta-analysis was to estimate the prevalence of HCV infection among older adults in long-term care (LTC) and assess factors associated with the prevalence of HCV in this setting. The Preferred Reporting Items for Systematic Review and Meta-Analyses checklist was used as the methodological guide. Two reviewers independently assessed the study quality using a validated modified quality assessment tool. Six articles met inclusion criteria; the majority were cross-sectional studies (83.3 %) designed to estimate HCV infection prevalence rates and identify associated risk factors. HCV prevalence ranged from 1.4 to 11.8 %. A pooled HCV infection prevalence of 3.3 % (95 % confidence interval: 1.5–7.2 %) was estimated based on 1920 LTC residents with substantial heterogeneity noted (Q = 51.1, p < 0.001; I 2 = 90.2). Three of six studies reported statistically significant factors associated with an increased risk for HCV infection, including older age, female gender, history of blood transfusions, short duration of LTC residence, and hepatitis B virus positivity. This study reports a higher prevalence of HCV infection among older adults in LTC settings compared to community-dwelling older adults; however, accurate estimation of prevalence is limited by heterogeneity between and within studies, variation in sampling and recruitment methodologies, and absence of the HCV-RNA test to confirm active infection.
Literature
1.•
go back to reference Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81. The high prevalence of global HCV infection highlights the urgency to identify and reduce the burden of complications and co-morbidities associated with infection. CrossRefPubMed Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81. The high prevalence of global HCV infection highlights the urgency to identify and reduce the burden of complications and co-morbidities associated with infection. CrossRefPubMed
2.
go back to reference Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.CrossRefPubMed Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.CrossRefPubMed
4.•
go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. The development of primary prevention methods are vital to reduce chronic diseases associated with infection and improve survival, especially among older adults. CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. The development of primary prevention methods are vital to reduce chronic diseases associated with infection and improve survival, especially among older adults. CrossRefPubMed
5.
go back to reference El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745–50.CrossRefPubMed El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745–50.CrossRefPubMed
6.••
go back to reference Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32. In the United States, new hepatitis C virus infection therapies have been shown to be effective in reducing disease progression and offering a virologic cure. Therefore, it is important to identify at risk cohorts (adults 65 years and older) to offer targeted testing, education, and care to increase quality of life. PubMed Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32. In the United States, new hepatitis C virus infection therapies have been shown to be effective in reducing disease progression and offering a virologic cure. Therefore, it is important to identify at risk cohorts (adults 65 years and older) to offer targeted testing, education, and care to increase quality of life. PubMed
7.
go back to reference Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol. 2011;9(1):71–8.CrossRefPubMed Omland LH, Jepsen P, Krarup H, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol. 2011;9(1):71–8.CrossRefPubMed
8.
go back to reference El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227–30.CrossRefPubMed El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227–30.CrossRefPubMed
9.
go back to reference Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–21. 521 e511-516.CrossRefPubMed Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–21. 521 e511-516.CrossRefPubMed
10.
11.
13.
go back to reference Mathei C, Niclaes L, Suetens C, et al. Infections in residents of nursing homes. Infect Dis Clin N Am. 2007;21(3):761–72.CrossRef Mathei C, Niclaes L, Suetens C, et al. Infections in residents of nursing homes. Infect Dis Clin N Am. 2007;21(3):761–72.CrossRef
14.
go back to reference Chien NT, Dundoo G, Horani MH, et al. Seroprevalence of viral hepatitis in an older nursing home population. J Am Geriatr Soc. 1999;47(9):1110–3.CrossRefPubMed Chien NT, Dundoo G, Horani MH, et al. Seroprevalence of viral hepatitis in an older nursing home population. J Am Geriatr Soc. 1999;47(9):1110–3.CrossRefPubMed
15.
go back to reference Marcus EL, Dahoudi N, Tur-Kaspa R. Hepatitis C virus infection among elderly patients in a geriatric hospital. Arch Gerontol Geriatr. 1994;19(3):213–21.CrossRefPubMed Marcus EL, Dahoudi N, Tur-Kaspa R. Hepatitis C virus infection among elderly patients in a geriatric hospital. Arch Gerontol Geriatr. 1994;19(3):213–21.CrossRefPubMed
16.
go back to reference Perz JF, Grytdal S, Beck S, et al. Case-control study of hepatitis B and hepatitis C in older adults: do healthcare exposures contribute to burden of new infections? Hepatology. 2013;57(3):917–24.CrossRefPubMed Perz JF, Grytdal S, Beck S, et al. Case-control study of hepatitis B and hepatitis C in older adults: do healthcare exposures contribute to burden of new infections? Hepatology. 2013;57(3):917–24.CrossRefPubMed
17.
go back to reference Floreani A. Hepatitis C: should antiviral therapy be offered to elderly patients? Nat Rev Gastroenterol Hepatol. 2009;6(9):503–4.CrossRefPubMed Floreani A. Hepatitis C: should antiviral therapy be offered to elderly patients? Nat Rev Gastroenterol Hepatol. 2009;6(9):503–4.CrossRefPubMed
18.
go back to reference Oze T, Hiramatsu N, Yakushijin T, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol. 2011;54(4):604–11.CrossRefPubMed Oze T, Hiramatsu N, Yakushijin T, et al. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J Hepatol. 2011;54(4):604–11.CrossRefPubMed
19.
go back to reference Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol. 2007;102(7):1383–91.CrossRefPubMed Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol. 2007;102(7):1383–91.CrossRefPubMed
20.
go back to reference Fischer GE, Schaefer MK, Labus BJ, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007–2008. Clin Infect Dis. 2010;51(3):267–73. Fischer GE, Schaefer MK, Labus BJ, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007–2008. Clin Infect Dis. 2010;51(3):267–73.
21.
go back to reference Schaefer MK, Jhung M, Dahl M, et al. Infection control assessment of ambulatory surgical centers. JAMA. 2010;303(22):2273–9.CrossRefPubMed Schaefer MK, Jhung M, Dahl M, et al. Infection control assessment of ambulatory surgical centers. JAMA. 2010;303(22):2273–9.CrossRefPubMed
22.
go back to reference Gutelius B, Perz JF, Parker MM, et al. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology. 2010;139(1):163–70.CrossRefPubMed Gutelius B, Perz JF, Parker MM, et al. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology. 2010;139(1):163–70.CrossRefPubMed
23.
go back to reference Perz JF, Thompson ND, Schaefer MK, et al. US outbreak investigations highlight the need for safe injection practices and basic infection control. Clin Liver Dis. 2010;14(1):137–51.CrossRefPubMed Perz JF, Thompson ND, Schaefer MK, et al. US outbreak investigations highlight the need for safe injection practices and basic infection control. Clin Liver Dis. 2010;14(1):137–51.CrossRefPubMed
24.
go back to reference Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–94.CrossRefPubMed Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147(8):W163–94.CrossRefPubMed
25.
go back to reference von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.CrossRef von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.CrossRef
26.
go back to reference Yaphe S, Bozinoff N, Kyle R, et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88(7):558–64.CrossRefPubMed Yaphe S, Bozinoff N, Kyle R, et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect. 2012;88(7):558–64.CrossRefPubMed
27.
go back to reference Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559–73.CrossRefPubMed Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559–73.CrossRefPubMed
28.
go back to reference Rothstein HR, Borenstein M. Publication bias in meta-analysis: prevention, assessment, and adjustments. West Sussex: John Wiley & Sons, Ltd.; 2005.CrossRef Rothstein HR, Borenstein M. Publication bias in meta-analysis: prevention, assessment, and adjustments. West Sussex: John Wiley & Sons, Ltd.; 2005.CrossRef
29.
go back to reference Baldo V, Floreani A, Menegon T, et al. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. The Collaborative Group. Gerontology. 2000;46(4):194–8.CrossRefPubMed Baldo V, Floreani A, Menegon T, et al. Prevalence of antibodies against hepatitis C virus in the elderly: a seroepidemiological study in a nursing home and in an open population. The Collaborative Group. Gerontology. 2000;46(4):194–8.CrossRefPubMed
30.
go back to reference Floreani A, Bertin T, Soffiati G, et al. Anti-hepatitis C virus in the elderly: a seroepidemiological study in a home for the aged. Gerontology. 1992;38(4):214–6.CrossRefPubMed Floreani A, Bertin T, Soffiati G, et al. Anti-hepatitis C virus in the elderly: a seroepidemiological study in a home for the aged. Gerontology. 1992;38(4):214–6.CrossRefPubMed
31.
go back to reference Maral I, Dogruman-Al F, Bakar C, et al. Hepatitis B virus and hepatitis C virus seroprevalence in the elderly living in nursing homes. J Investig Med. 2009;57(6):717–9.PubMed Maral I, Dogruman-Al F, Bakar C, et al. Hepatitis B virus and hepatitis C virus seroprevalence in the elderly living in nursing homes. J Investig Med. 2009;57(6):717–9.PubMed
32.
go back to reference Simor AE, Gordon M, Bishai FR. Prevalence of hepatitis B surface antigen, hepatitis C antibody, and HIV-1 antibody among residents of a long-term-care facility. J Am Geriatr Soc. 1992;40(3):218–20.CrossRefPubMed Simor AE, Gordon M, Bishai FR. Prevalence of hepatitis B surface antigen, hepatitis C antibody, and HIV-1 antibody among residents of a long-term-care facility. J Am Geriatr Soc. 1992;40(3):218–20.CrossRefPubMed
33.
go back to reference Mansour-Ghanaei F, Fallah MS, Jafarshad R, et al. Seroprevalence of hepatitis B and C among residents of Guilan nursing home. Hepat Mon. 2007;7(3):139–41. Mansour-Ghanaei F, Fallah MS, Jafarshad R, et al. Seroprevalence of hepatitis B and C among residents of Guilan nursing home. Hepat Mon. 2007;7(3):139–41.
35.
go back to reference Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.CrossRefPubMed Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.CrossRefPubMed
36.
go back to reference Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147–71.CrossRefPubMed Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147–71.CrossRefPubMed
Metadata
Title
Burden of Hepatitis C Virus Infection Among Older Adults in Long-Term Care Settings: a Systematic Review of the Literature and Meta-Analysis
Authors
Kimberly J. Alvarez
Arlene Smaldone
Elaine L. Larson
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 4/2016
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-016-0518-9
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.